PP
ADMS

Paloma Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

Paloma Partners’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-53,219
Closed -$136K – 2652
2020
Q2 		$136K Buy
+53,219
New +$156K ﹤0.01% 1830
2020
Q1 		– Sell
-10,239
Closed -$39K – 2315
2019
Q4 		$39K Buy
+10,239
New +$49K ﹤0.01% 2087
2019
Q1 		– Sell
-24,200
Closed -$207K – 2046
2018
Q4 		$207K Buy
+24,200
New +$315K 0.01% 1045

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Paloma Partners's ADMS Position: Q3 2020 in Review

Paloma Partners sold out of Adamas Pharmaceuticals (ADMS) in Q3 2020, closing a stake of 53,219 shares — an estimated $136K sold.

Paloma Partners first reported a position in ADMS in Q4 2018 and held it in 3 quarters. The position peaked at $207K in Q4 2018. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2020.

  • Paloma Partners reported no remaining Adamas Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 53,219 Adamas Pharmaceuticals shares in Q3 2020, an estimated $136K.
  • Paloma Partners first reported a position in Adamas Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Paloma Partners's Adamas Pharmaceuticals position peaked at $207K in Q4 2018.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.